Czogalla, Bastian http://orcid.org/0000-0001-6589-4736
Deuster, Eileen
Liao, Yue
Mayr, Doris
Schmoeckel, Elisa
Sattler, Cornelia
Kolben, Thomas
Hester, Anna
Fürst, Sophie
Burges, Alexander
Mahner, Sven
Jeschke, Udo
Trillsch, Fabian
Article History
Accepted: 13 June 2020
First Online: 22 June 2020
Compliance with ethical standards
:
: Thomas Kolben holds stock of Roche AG and his relative is employed at Roche AG. Anna Hester has received a research grant from the “Walter Schulz” foundation and advisory board, speech honoraria, and travel expenses from Roche and Pfizer. Research support, advisory board, honoraria, and travel expenses from AstraZeneca, Clovis, Medac, MSD, Novartis, PharmaMar, Roche, Sensor Kinesis, Tesaro, and Teva have been received by Sven Mahner and others from AstraZeneca, Medac, PharmaMar, Roche, Tesaro by Fabian Trillsch. All other authors declare no conflict of interest. All the above-mentioned companies did not influence the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
: This study was approved by the Ethics Committee of the Ludwig-Maximilians-University, Munich, Germany (approval numbers 227–09 and 18–392). The ovarian cancer specimens were obtained in clinically indicated surgeries and initially used for histopathological diagnostics. When the current study was performed, all diagnostic procedures were completed, and the patients’ data were anonymized. The ethical principles adopted in the Declaration of Helsinki 1975 have been respected.
: All authors have read the manuscript and agree to its publication.